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Over the past two decades, numerous randomised trials exploring the efficacy of cervical cancer 
screening in intervention and control groups have been conducted across India. The trials have 
attracted both scrutiny and regulatory action for their failure to adhere to the ethical standards 
expected of the clinical research community (Baggchi, 2014). Exploration of the ethical malpractice 
in the Tamil Nadu cervical cancer trial, and examination of the context in which the trial was 
conducted form a basis for consideration of how research practitioners can act as exemplars and 
enablers of ethical research. An improvement plan is proposed for individual research practitioners 
working on clinical trials; incorporating educational and professional development requirements, 
evidencing of key research skills with the aim of issuing a standardised framework for the job role 
to contribute to quality assurance processes and ensure safe and ethical research practice.  
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Introduction 
Cervical cancer is one of the most common cancers to present within developing countries 
(Sankaranarayanan, 2013), with a number of recent cervical cancer trials taking place in India. 
Three of these trials, beginning in Mumbai in 1998 (Srinivasan, 2013), with data collection 
continuing in Osmanabad and Tamil Nadu until 2003 (Sankaranarayanan et al, 2007) were funded 
by foundations within the US and have drawn criticism in a recent report published by The Indian 
Journal of Medical Ethics (Srinivasan, 2013). The context to which these studies belong is 
particularly relevant in highlighting the ethical misconduct of the trials. Ethical permission was 
received for the studies during the same time period in which pressure groups (Herson, 1998) were 
active in their objection to the use of Randomised Control Trials in maternal HIV transmission 
research (Srinivasan, 2013). These criticisms led to amendments to the Declaration of Helsinki’s 
ethical guidelines on medical research. The Declaration changes detail the acceptability of placebo 
or no treatment, only when a null hypothesis exists (Srinivasan 2013). The trials conducted in India 
were not designed to test a null hypothesis, rather a known intervention was denied to the control 
groups of each of the three studies. These events suggest that clinical equipoise, the foundation for 
ethical justification of RCTs, was not present; both an ethical and institutional breach of clinical 
research practice.  
What is perhaps most disturbing about the ethical failings of these trials is that such a design 
would not have been approved by the regulatory bodies within the nations providing monetary 
funding for the trials, namely the United States (US). Indeed, the US Office for Human Research 
Protections ruled that mechanisms for providing relevant information about the trial to participants 
to allow them to give informed consent were not in place (Bagcchi 2014).  Instead, the trials were 
outsourced to India where healthcare infrastructure and medical regulation standards differ from the 
US, thus enabling clinical trials of poor ethical standards to be conducted. Whilst there are clear and 
definite disparities in healthcare services between India and the US, this is more related to equity of 
access rather than a marked difference in cervical screening practices. The Indian government (and 
private practices) offer cytology-based services, much like the US,  (Sankaranarayanan 2013) which 
additionally makes use of the Papanicolaou test as a screening method for cervical cancer through 
extraction and testing of cervical cells for abnormality (Storck, 2014).  As the services offered by 
both nations (trial host and trial funder) are comparable to a significant extent, ethical malpractice 
can be identified in that a) a known to be effective intervention was withheld from the control 
groups of the Indian trials; and b) the intervention is one that is routinely provided and practiced by 
the healthcare services of the trial hosting country. 
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These cervical cancer trials, like many others are representative of the globalisation of 
clinical research. Within a liberal economy, work is allocated to bidder offering the lowest price and 
developing countries such as India are able to offer lower operational costs, less bureaucracy and 
quicker clinical testing timelines than their Western counterparts (Glickman et al., 2009), making 
them a more attractive hosting location for pharmaceutical companies. The ethical implications of 
globalisation are numerous and include, as highlighted by London (2002) discrepancies in 
educational levels and social structures may disadvantage research participants and jeopardise their 
ability to provide informed consent. A resulting report from The US Office for Human Research 
Protections has deemed that the trial participants in two (Mumbai and Osmanabad) of the studies 
were not given appropriate levels of information to enable them to give full informed consent to the 
study, and that the design of the trials investigated were unethical in their withholding of 
established healthcare interventions (Baggchi, 2014). Pandiya (2011) cites the regulatory concern 
around the ethical oversight in Indian clinical trials; the quality of ethics committees including 
operational procedures, administrative functions and regularity of meetings were recognised as both 
problematic and detrimental to the quality of the committee function. 
 
Due to the amount of criticism the trials have drawn, the purpose of this appraisal is to 
assess the ethical failings of one of the three studies targeted for its poor conduct, and to propose a 
framework to provide assurance that such practice would avoid being repeated. The Tamil Nadu 
screening trial was chosen as, to date it has escaped the level of scrutiny afforded to the two trials to 
which it is related (Srinivasan, 2013), although its design and quality of conduct was largely 
similar. The primary outcome of the study measured the incidence and mortality rates of cervical 
cancer in the Tamil Nadu district of India.  One hundred and fourteen clusters of women, 57 in both 
the interventions and control groups, made up the study cohort. Depending on allocation, women 
were given either existing care or visual inspection with 4% acetic acid (VIA; Sankaranarayanan, 
2013). The results of the study showed that the intervention group benefitted from “a significant 
25% reduction in cervical cancer incidence and a 35% reduction in cervical cancer mortality 
compared with the control group” (Sankaranarayanan, 2013, p. 221). In designing a trial that 
produces results such as these, based on the withholding of an established and recognised 
preventative procedure, immediately the issue of clinical conflict presents itself.  
To address this, Western cervical cancer screening practices were examined. Within the UK, 
the National Institute for Health Care Excellence recommends that all women between 25 and 64 
years old are eligible for cervical screening (NICE, 2010). Similarly, US standards recommend that 
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screening should take place from the age 21, but does not specify the frequency of screening 
(Centre for Disease Control, CDC, 2014) or any further specific details. Both organisations practice 
systems to appraise research evidence and develop health guidance and recommendations for 
national healthcare providers. Research evidence used to form the NICE guidance dates as far back 
as 1980 (CDC, 2014), which suggests that when the 2007 Tamil Nadu study was designed and 
implemented, a null hypothesis (needed to justify actively offering screening to only one group 
within the trial) was not present. To elaborate, evidence already existed that recommended 
screening for cervical cancer as a preventative service, making the design of the 2007 trial 
unethical. 
To specify the care given to each group within the study: 1) the control group were not 
actively screened; they were given advice on how to access screening, signs and symptoms of 
cervical cancer, early diagnosis and treatment; 2) the intervention group were invited for visual 
inspection with 4% acetic acid (VIA) screening, and given details of where the screening would 
take place. Participants were randomly assigned to each grouping (CDC, 2014).  It was argued that, 
although the control group were not invited to a screening appointment, they were educated on the 
benefits of screening and given the appropriate information to pursue access to such services. No 
information was withheld from the group. It may be reasonable to assume that if control 
participants wished to be screened, then they easily could have done so, and therefore the design 
(independent of the null hypothesis issue discussed above) of the study is in fact ethical. However 
the issue with this approach is its failure to take account for equity of access to screening: 
participants in the intervention group were privileged in their access to screening, there were no 
logistical issues as in the control group, who had to organise their own access. It is reasonable to 
suggest that this inequity may be more acceptable if the study were taking place within a country 
with a more developed healthcare infrastructure that was able to offer cervical screening as a 
routine practice; the US and UK guidance documents previously discussed are examples of such 
infrastructure that could enable participants within the control group of the Tamil Nadu study to 
access the screening that had been given information on, more easily1. Furthermore, it has been 
proposed that this aspect of the trial does not enable participants to give informed consent to 
involvement within the study, as the information given to the control group could mislead 
participants into believing that what they are receiving is in fact “standard care” (whilst the 
                                                 
1
 Randomised controlled trials by virtue of design will provide differing treatments to participants groups in order to 
test a hypothesis and elicit data, thus adhering to the overarching goal of clinical research in developing generalisable 
knowledge. Differences in treatments are not always concomitant to a difference in standards of risk safety, particularly 
when established and accepted treatments are readily accessible. As such, organisations designing clinical research 
should embody this basic standard of limiting harm to research participants.  
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intervention group receive a special “non standard” treatment). This is not the case, as the 
interventional screening method used, is in fact available in India (Baggchi, 2014). Participants, 
therefore are consenting to potentially belonging to a group within the trial that not only has been 
misinformed on the standard of care available to them, but also one that has been denied the 
opportunity to access a routine care practice, itself an unethical practice.  
It is not within the scope of this analysis to examine every contributing factor that enabled 
the study to gain ethical clearance and approval, however Baggchi (2014) provides an overview of 
the reaction to the Tamil Nadu trial, and two other similar studies, including the results of a report 
from The US Office for Human Research Protection which states that withholding healthcare that is 
known to be effective from control groups is seen as unethical, and has caused much controversy 
over the application of this standard within deprived geographic areas (Baggchi, 2014). 
Clearly the concern with the ethics of the trial lay firstly with the design of the study: no 
provision of access was planned for, or provided. Secondly, the regulatory measures in place to 
protect participants from unsafe research were applied in a professionally questionable manner, thus 
resulting in a situation where an unnecessary number of lives were lost to a disease whose 
presentation can be considerably reduced via screening programmes. This is a significant example 
of poor ethical and clinical governance conduct, evidencing three specific aspects of the research 
process where policy and process can be bettered to improve both medical outcomes and research 
quality: a) research design: as identified above, only a null hypothesis could justify actively 
withholding a recognised intervention from the control group (it is entirely possible that the trial 
could have been designed in a more ethically robust manner and still evaluated the hypothesis 
effectively); b) ethical consideration: the US Office For Human Research Protection has recognised 
that withholding recognised interventions as unethical, yet the reviewing ethical bodies of the 
Christian Fellowship Community Health Centre and IARC approved the project (cited in - 
Sankaranarayanan, 2007, p.398; and c) informed consent: the Declaration of Helsinki states that all 
consent to research must be informed consent, and that potential participants should understand any 
information about the research given to them (World Medical Association, 2013). 
 
Scope and Content of the Developmental Framework  
Much of what is identified above stems from institutional flaws and/or neglect in legislation, 
subsequent planning and execution of the study that would be extremely difficult to rectify on the 
individual level of the research practitioner (the professional whom the development framework 
section of the document has been developed for). Nevertheless, research practitioners are an integral 
ETHICAL MALPRACTICE IN CLINICAL TRIALS                                                                   54 
Pierce, N. (2015) Ethical Malpractice in Randomised Controlled Trials in India: An Appraisal and Improvement Pro-
posal. Journal of Applied Psychology and Social Sciences, 1 (1), 49-62 
part of any clinical trial, and it is important that their data collection methods and treatment of study 
participants are of high professional and ethical standards. It is hoped that where this is the case, a 
proportion of the risks associated with participation in research, particularly regarding informed 
consent, could be mitigated.  Within this analysis, research practitioners are defined as members of 
the following professions working in the clinical research field (as either Research Assistants, 
Clinical Studies Officers, Research Nurses or Research Practitioners) and will be referred to 
throughout this paper as Research Practitioners: Nurses, Allied Health Professionals (Occupational 
Therapists and Physiotherapists) Psychologists, Life Sciences or Social Sciences graduates. 
The proposed competency framework (see Table 1) for clinical research practitioners will: 
Identify a set of core competencies and values that research staff working in clinical trials should 
embody; propose a method of evidencing these core competencies and values, with a view to 
assessment and appraisal of such, and stipulate essential qualifications and training that research 
practitioners should possess or work towards as part of their Professional Development Planning 
(PDP).  This framework addresses problems within ethical practice and informed consent by: 1) 
Enabling research practitioners to be suitably trained and qualified to practice within their field in 
an ethical manner; 2) Ensuring research practitioners are competent to take informed consent from 
research participants including capacity assessment, addressing the potential risks and benefits 
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Table 1. 
 
A proposed Competency Framework for Clinical Research Practitioners working in Clinical Trials 
  Education and Training requirements 
Undergraduate training in Nursing, Allied Health Professions or Psychology. 
Formal clinical training will provide a robust foundation in knowledge of psychical/mental 
wellbeing, allow practitioners to work confidently with clients as autonomous professionals.  
Postgraduate training as above is desirable, as it is at this level that professionals will begin to 
develop specialist knowledge in their chosen field, providing expert care services. 
Completion of International Conference for Harmonisation Good Clinical Practice training and 
commitment to annual updates. GCP training standardises individual clinical research practice 
activity and ensures researchers are aware of the importance of conducting their duties in a safe 
and ethical manner (National Institute of Health Research, n.d) 
Completion of Informed Consent training: General training, extending to Adults Lacking Capacity 
and Paediatric Consent where appropriate. 
Completion of Information Governance Training. 
Proficiency in the use of complex IT systems, including institutional databases (e.g. EMIS, PAS), 
bespoke data entry systems (e.g. individualised study recruitment databases) and secure data 
transfer methods.  
A commitment to maintaining the standards required by an individual’s profession for Health 
Care Professionals Council registration. 
 
It has been proposed that in order to work within the professional and ethical bounds of the 
health and social science professions as a researcher, specialist training to cover the ethical and 
legal responsibilities of the role are necessary (McDermott et al., 2014), with similar observations 
have made regarding the work of social sciences researchers (Drotar, 2013).  Taking informed 
consent as an example of mandatory training for Research Practitioners in reference to the concerns 
reported around the quality of the consent given by trial participants, it is imperative that the 
definition of informed consent is understood in full. Further to this Research Practitioners must be 
able to communicate the need for informed consent to participants, and work in partnership with 
them to provide appropriate levels of information on the scope and objectives of the study, the roles 
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of all involved,  how data will be collected and analysed and how confidentiality will be assured 
(this list is not exhaustive). Research Practitioners must also be sure to document the consent 
process, and seek consent at each additional phase of the study, for example at the start of a new 
treatment or intervention regimen. An overarching concern within the consent process is that of 
capacity; the practitioner as an individual must be sensitive to judging the capacity of the participant 
to consent to involvement in research. UK legislation such as the Mental Capacity Act (2005) is an 
example of guidance that is available for researchers to reference; however policies such as these 
would clearly have no claim to enforcement in the Tamil Nadu case study. Informed consent 
enables individuals to be treated in a dignified and respectful manner, acknowledging their 
autonomous personhood; to circumvent this process, from a Kantian perspective would not only 
violate this personhood, but use individuals, itself a disingenuous act (Gregory, 2003). 
As demonstrated here, the vast array of both clinical and legislative literature surrounding 
clinical research requires its own commitment from the Research Practitioner, to ensure that a 
comprehensive working knowledge of both current and established professional education is 
maintained. Commonly referred to as Continuous Professional Development (CPD),  it is an 
important aspect of the Research Practitioner’s role, and therefore the education and training 
requirements detailed here are representative of the minimum standards that individuals should 
possess upon entry to the role. Tools such as the Researcher Development Framework (RDF; a tool 
intended for international use and developed in 2009 by the Careers Research and Advisory Centre) 
clarify the expected standards for researchers to meet, including the academic and person-centred 
skills needed to promote and advance research (Vitae, 2014). Research Practitioners using such 
resources are able to identify their strengths, areas of work that possess scope for improvement and 
search for appropriate opportunities to enable them to develop within their role (Vitae, 2014). It is 
usually expected that tools such as the RDF will also be utilised by Research Practitioners to assist 
in development of a CPD portfolio, used to exhibit commitment to learning and development of 
practice; the appropriateness and feasibility of such a system being utilised in India, is debatable. 
General standards of healthcare vary across both India and its public and private healthcare systems, 
with maternal and women’s health a priority within Indian healthcare reform (Srivastava et al., 
2014).  However, in an economy where economic growth has not resulted in improved health for all 
(Subramanian & Subramanyam, 2011), the use of public funds to develop all but the most critical 
healthcare infrastructure is an ethically dubious notion.  
Development opportunities available to Research Practitioners can vary and can include 
providing training to junior colleagues, coordinating promotional and outreach programmes to 
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wider staff groups and the general public, and supervision or line management of other research 
staff. It is generally expected that Research Practitioners in all but the most junior levels will 
possess a postgraduate qualification in a healthcare science or clinical research subject (NHS, 
2014). It is recognised that researchers within the NHS may be encouraged to use a localised edition 
of the recently simplified NHS Appraisals Toolkit (NHS Employers, 2010). Both materials are 
useful, however it should be noted that the RDF is developed specifically with researchers in mind; 
the NHS Appraisals Toolkit is generic and adaptable to each job role, the limitations of which 
should be acknowledged. For example, an appraisal tool that is unable to recognise and account for 
the specific professional duties and career paths of clinical researchers will be less effective than 
one that is able to provide comprehensive and holistic guidance.  Research Practitioners should 
therefore, (dependent on their employment sector) assess the range of CPD resources available to 
them and select based on which material they feel will best enable them to plan and fulfill their 
CPD requirements (Health and Care Professions Council, 2009). Again, these are Western 
frameworks and initiatives and intended as only as an example of how clinical research can 
compliment and be integrated into healthcare systems. 
 
Essential Skills for Research Practitioners 
The skills necessary for Research Practitioners may be identified and discussed as part of 
the educational and training activities detailed above. However, the development of such skills in 
isolation and without acknowledgement of the context within which they sit will not be conducive 
to the development of a competent and effective Research Practitioner. Instead, it may be helpful to 
think of skills needed for a role as the components of competence, defined as performance and 
behaviour standards required for successful performance at work (Chartered Institute of 
Professional Development, 2014). Harvard University’s Joint Task Force for Clinical Trial 
Competency, a partnership between Harvard and leading pharmaceutical companies that 
amalgamates  education and training for professionals working within clinical research (Li, 2014), 
identified a set of Competency Domains for best practice in clinical research. These competencies 
span across the entirety of the professional researcher’s job role and provide a framework for skills 
development, in that researchers are able to attribute their skill sets to particular domains, thus 
identifying both strengths and areas for development.   
 
Evidencing Key Competencies: Skills Frameworks 
The Royal College of Nursing (RCN) provides a framework for Clinical Research Nurses to 
assess and document their level of competency in each area of practice deemed relevant to Clinical 
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Research (RCN 2011). Although designed for research nurses, much of the framework is adaptable 
for those without a nursing background (instead possessing Psychology, Occupational Therapy or 
other AHP training). It is accepted that not all Research Practitioners work within the NHS; 
however until a more general framework for practitioners of varying backgrounds is developed to 
map key generic research skills, it is useful to draw upon existing resources. Each competency 
detail provides an assessment space, in which practitioners are able to document evidencing of 
relevant key skills at the appropriate level of complexity. Whilst this tool could be used as personal 
mapping and records of achievements, it is advised by the RCN that guidance from mentors will aid 
the assessment cycle (RCN 2011).   
 
Clinical Supervision 
The process of clinical supervision is defined as the acting of supervisors and practitioners 
formally coming together to reflectively evaluate supervisee practice, and working in unison to 
more fully understand professional issues through problem solving and critical appraisal (Fowler, 
1998).  Clinical supervision is defined by Fowler as an evolving definition that applies differently to 
each clinical setting and level of competence. This is especially relevant to the role of the Research 
Practitioner, whom not only works clinically, but is also expected to develop an intimate knowledge 
of research policy, and the ever advancing pharmaceutical industry. Indeed, the expansive role of 
the Research Practitioner as an academically educated professional is used by Severinnson (2014) 
to illustrate the supervision process as pedagogical within a professional context. It is expected 
then, that clinical supervision will function as a beneficial process for the Research Practitioner to 
enable self-reflection and development, as well as providing a forum to evidence mastery of 
relevant competencies (in line with the aforementioned skills frameworks). In addition, clinical 
supervision should be considered for its benefits to employers, in acting as a “quality control” 
process to identify and evaluate skills and areas of concern within individual employee practice.  
 
Conclusion 
The aim of this paper has been to consider the role of the research practitioner in relation to 
the clinical governance of clinical research trials. Whilst it is accepted that the failings and 
malpractice involved in the Tamil Nadu trial are complex and involve multiple agencies, there is 
also much that can be done by the individual research practitioner to safeguard the rights and safety 
of research participants. As the individuals who are at the “front line” of research, and whom 
typically have the most contact with study participants, often developing meaningful relationships 
over the course of the study, the research practitioner has a pivotal role in safeguarding the dignity 
ETHICAL MALPRACTICE IN CLINICAL TRIALS                                                                   59 
Pierce, N. (2015) Ethical Malpractice in Randomised Controlled Trials in India: An Appraisal and Improvement Pro-
posal. Journal of Applied Psychology and Social Sciences, 1 (1), 49-62 
and safety of study participants. It is hoped that the detail of necessary skills and formats of 
evidencing such will highlight the role of the research practitioner as instrumental in the ethical and 
safe delivery of clinical trials, particularly regarding the facilitation of informed consent within the 
participant’s decision making process (Pick et al., 2013). The framework provided is 
comprehensive in its scope of the standards to which Research Practitioners should adhere, without 
the burden of geographical and regional limitations. By specifying only the discipline and level of 
qualifications required for the profession, the framework may be implemented on a global scale, 
allowing sensitivity to cultural and geographical practices whilst also providing a pragmatic 
solution to standardisation of skill mix within the profession. Furthermore, completion of courses 
such as the ICH GCP training can be achieved via a variety of formats, including web based 
learning and trainer facilitated classes, making learning both accessible and cost effective.  
It is apparent that the Tamil Nadu randomised controlled trial was neither designed nor 
regulated in a manner that acknowledged the duty of care owed to the study participants by way of 
their involvement in the project. Both the Declaration of Helsinki and the widely recognised ethical 
precedent of clinical conflict were circumvented, with the outcomes of significant mortality rates 
and damage to the reputation of clinical research. Whilst it remains to be seen what the long term 
effects of the misconduct of the Tamil Nadu and other two Indian cervical cancer trials will be for 
the clinical research community, the loss of life and international attention garnered should be of 
considerable concern to the regulatory bodies, funders and central study team involved. It is hoped 
that the resulting scrutiny will enable a reflexive approach to the problems and failings, and provide 
a foundation for the appraisal and improvement of the clinical trials outsourcing process. 
Discouragingly there is already a substantive body of writing on the implications of outsourcing 
clinical trials, many of which justify outsourcing as a method for bringing treatment to market more 
rapidly (Bansal, 2012). However to make this the primary objective in outsourcing would be a 
mistake; this aim would fail to acknowledge that the foundation of professional clinical research 
lies in ethical practice and just treatment of participants. Only by adopting this philosophy as an 
overarching objective can clinical research justifiably develop clinical knowledge. 
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